Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FULVESTRANT MEK2 Gene Mutation	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Fuzuloparib Childhood Obesity	University of South Carolina	P1/2	CCC (52)
gfh018 Cancer	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CCC (52)
Gilteritinib Non-Small Cell Lung Carcinoma	Astellas Pharma Global Development, Inc.	P1/2	CCC (52)
Gsbr-1290 Type 2 Diabetes Mellitus	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	P1/2	CCC (52)
gsk1120212 Thyroid Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CCC (52)
gsk2110183 Gastroesophageal Adenocarcinoma	Laekna Limited	P1/2	CCC (52)
gsk2110183 Neoplasm	Laekna Limited	P1/2	CCC (52)
hcw9218 Exocrine Pancreatic Carcinoma	ImmunityBio, Inc.	P1/2	CCC (52)
hem101 Acute Lymphoblastic Leukemia	National Research Center for Hematology, Russia	P1/2	CCC (52)
Hrs-4642 Advanced KRAS G12D Mutant Solid Tumors	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CCC (52)
Hrs-5041 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CCC (52)
HUMAN FAECAL MATTER Melanoma	The Netherlands Cancer Institute	P1/2	CCC (52)
Human signal regulatory protein alpha (SIRP alpha variant V2 extracellular D1 domain, SIRP alpha V2D1) fragment 31-163, comprising the first two extracellular loops of the D1 domain, [N<sup>110</sup>>A<sup>80</sup>]-variant, anti-(human CD47, integrin associated protein (IAP)) (1-133 in the current sequence) fused via a (G4S) 2 peptide linker (134-143) to gamma 1 heavy chain (144-594) [VH (Mus musculus IGHV1-1201 -(IGHD) -IGHJ101, CDR-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo sapiens IGHG103(CH1 (265-362), hinge (363-377), CH2 S<sup>445</sup>>A, E<sup>480</sup>>A, K <sup>481</sup>>A (378-487), CH3 (488-592), CHS (593-594)) (265-594)], (367-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (Mus musculus IGKV4-7201 -IGKJ101, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC01 (107'-213')]; dimer (373-373'':376-376'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa B-Cell Non-Hodgkin Lymphoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1/2	CCC (52)
hx009 Lymphoma	Hangzhou Hanx Biopharmaceuticals, Ltd.	P1/2	CCC (52)
Hydroxychloroquine Renal Cell Carcinoma	Leonard Appleman	P1/2	CCC (52)
Ibentatug Biliary Tract Cancer	ZielBio, Inc.	P1/2	CCC (52)
Ibentatug Ovarian Serous Cystadenocarcinoma	ZielBio, Inc.	P1/2	CCC (52)
Ibentatug Pancreatic Ductal Adenocarcinoma	ZielBio, Inc.	P1/2	CCC (52)
ibi133 Locally Advanced Unresectable or Metastatic Solid Tumors	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CCC (52)
ibi363 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (52)
Ibio123 COVID-19	Immune Biosolutions Inc	P1/2	CCC (52)
Imm-6-415 Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (52)
Imm-H014 Metabolic Dysfunction-Associated Steatohepatitis	Changchun Intellicrown Pharmaceutical Co. LTD	P1/2	CCC (52)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)

Showing 576 to 600 of 8,400 assets

PreviousPage 24 of 336Next